Last reviewed · By GLP1 Sidekick Editorial · 4 min read
The short answer
There are five official ways to lower GLP-1 costs in 2026: manufacturer savings cards for people whose commercial insurance covers the drug (as little as $25), the makers’ direct self-pay pharmacies (LillyDirect and NovoCare, from $149–$449 a month), TrumpRx.gov’s price listings, the Medicare GLP-1 Bridge ($50 a month if eligible), and income-based patient assistance programs. Which one applies depends almost entirely on your insurance type.
This guide is educational and not medical advice. It does not give dosing instructions. Talk to your prescriber or pharmacist about your own situation.
As little as $25 a month, with monthly/annual caps
Commercial insurance that doesn’t cover it, or no insurance
LillyDirect or NovoCare self-pay; TrumpRx.gov to compare
$149–$449 a month depending on drug and strength
Medicare Part D
Medicare GLP-1 Bridge (if you meet the criteria)
$50 a month
Low income, Medicare or uninsured
Novo Nordisk Patient Assistance Program; Lilly Cares
Free if eligible (medicine lists vary)
Manufacturer copay cards exclude anyone in a government program such as Medicare, Medicaid, TRICARE or the VA. That’s why Medicare enrollees look at the Bridge instead.
What do the manufacturer savings cards cover?
Zepbound savings card (Lilly): as little as $25 for a 1-, 2- or 3-month fill of the single-dose pen when your commercial plan covers it; maximum savings $100 per month and $1,300 per year; card ends Dec. 31, 2026.
Wegovy savings offer (Novo Nordisk): as little as $25 for the pen or pill with commercial coverage, subject to a maximum saving of $100 a month.
Foundayo savings card (Lilly): as little as $25 a month for eligible commercially insured patients with coverage.
Mounjaro and Ozempic (type 2 diabetes): each maker has its own copay program—check the official Mounjaro savings page and NovoCare for current terms.
How do LillyDirect and NovoCare self-pay work?
Both makers now sell brand-name medicine directly to cash-paying patients with a valid prescription, delivered to your door or picked up at a partner pharmacy.
Program
Medicines
Self-pay price (per month)
LillyDirect
Zepbound KwikPen or vial
$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with refill within 45 days)
LillyDirect
Foundayo pill
$149–$299 (some prices temporary through Dec. 31, 2026)
NovoCare
Wegovy pen
$199 intro for new patients’ first 2 low-strength fills (through Dec. 31, 2026), then $349; Wegovy HD $399
NovoCare
Wegovy pill
$149–$299
TrumpRx coupon
Ozempic pen
$199 for new self-pay patients’ first 2 fills of 0.25/0.5 mg (11/17/2025–12/31/2026), then $349 ($499 for 2 mg)
TrumpRx.gov is a federal website launched in February 2026 that lists cash prices for brand-name drugs and sends you to each maker’s program or gives you a coupon to use at a pharmacy. It doesn’t sell medicine or take insurance. It’s a handy one-stop price check if you’re paying cash. If your insurance covers your GLP-1, check your copay first—it may be lower. Medicare.gov notes TrumpRx purchases don’t count toward Medicare deductibles or out-of-pocket limits.
Are there free GLP-1 programs?
Possibly, depending on income and the medicine. Novo Nordisk’s Patient Assistance Program (2026) is for US citizens or legal residents with Medicare or no insurance and a qualifying household income; for uninsured patients the limit is at or below 200% of the federal poverty level for Ozempic and 400% for its other covered medicines. The Lilly Cares Foundation provides certain Lilly medicines free to qualifying patients. Check each program’s current medicine list—weight-management drugs aren’t always included.
What should I avoid?
Avoid sites selling “generic” or compounded semaglutide or tirzepatide. The FDA says compounded versions are not FDA-approved and has warned about dosing errors and counterfeit products. GLP1 Sidekick lists only FDA-approved, brand-name sources and official programs.
How do I check whether my insurance covers my GLP-1?
Start with your plan’s drug list (formulary) or member services. Both makers also offer coverage checks: Lilly has an online insurance checker for Zepbound and Foundayo, and LillyDirect says it checks coverage and helps with prior authorization if you choose to use commercial insurance. Lilly also notes that Zepbound coverage has been restored on select CVS Caremark formularies. If your plan requires prior authorization, your prescriber’s office usually submits it.
Can I use my HSA or FSA?
Lilly lists Zepbound and Foundayo as HSA/FSA eligible, noting that eligibility varies by plan, so check with your benefits administrator. Self-pay savings programs generally say you can’t also submit those purchases to insurance for reimbursement—read each program’s terms.
Quick answers
How can I get Zepbound or Wegovy for $25?
You need commercial insurance that covers the medicine. Lilly’s Zepbound savings card and Novo Nordisk’s Wegovy savings offer can then bring the cost to as little as $25, with a maximum saving of $100 a month (Zepbound also caps savings at $1,300 a year; its card ends Dec. 31, 2026). People on Medicare, Medicaid or other government plans aren’t eligible.
What is the cheapest way to get a GLP-1 without insurance in 2026?
The lowest official cash prices are $149 a month for the starting strengths of the Wegovy pill and Foundayo. Injectable options start at $199 (Wegovy pen intro offer for new patients) and $299 (Zepbound KwikPen or vial). Your prescriber decides which medicine and strength is right for you.
Can I use a manufacturer savings card with Medicare?
No. Lilly’s and Novo Nordisk’s copay cards exclude Medicare and other government programs. Eligible Medicare Part D enrollees can instead use the Medicare GLP-1 Bridge for $50 a month.
Lilly's official savings program for Zepbound, plus self-pay and Medicare options on one page.
Why it helps on a GLP-1: With commercial insurance that covers Zepbound pens, eligible patients may pay as little as $25 for up to a 3-month fill. Government insurance excluded.
As little as $25 with coverage (limits apply)Visit site →
Eli Lilly's direct-to-patient pharmacy for Zepbound, Foundayo, and other Lilly medicines, with home delivery.
Why it helps on a GLP-1: Self-pay Zepbound vials and KwikPens start at $299/month for the starter dose, and Foundayo pills start at $149/month—no insurance needed (prescription required).
Zepbound self-pay $299–$449/mo (refill within 45 days); Foundayo from $149/moVisit site →
Novo Nordisk's own pharmacy for self-pay Wegovy (pen and pill) and Ozempic, delivered to your door.
Why it helps on a GLP-1: New patients pay $199/month for the first two fills of the two lowest Wegovy pen doses (through 12/31/2026), then $349/month; Wegovy pill starts at $149/month.
Wegovy pill $149–$299/mo; pen $199 intro, then $349/moVisit site →
Federal website listing negotiated cash prices for brand-name GLP-1s and linking to each maker's program.
Why it helps on a GLP-1: A quick way to compare starting cash prices for Wegovy, Ozempic, Zepbound, and Foundayo in one place. It doesn't sell drugs itself.
Lists Wegovy pill from $149, Zepbound from $299Visit site →
Free Novo Nordisk medicines for people who qualify based on income and coverage.
Why it helps on a GLP-1: If you're uninsured or on Medicare with limited income, this may cover certain Novo medicines at no cost—check the current covered-medicine list.
Lilly's official copay card for Mounjaro (tirzepatide) for type 2 diabetes.
Why it helps on a GLP-1: Eligible commercially insured patients may pay as little as $25 for up to a 3-month prescription. Government insurance excluded.
As little as $25 with coverage (limits apply)Visit site →
Prices and program terms change often; we re-check them on the official pages listed above. Listings are not endorsements, and we never list compounded semaglutide or tirzepatide sellers. Spot something outdated? Email hello@glp1sidekick.com.
Medical disclaimer: This guide is educational and not medical advice. It does not give dosing instructions. Talk to your prescriber or pharmacist about your own situation. If you have a medical emergency, call 911. Read our full disclaimer.